Enterprise Value

18.66M

Cash

47.14M

Avg Qtr Burn

-2.03M

Short % of Float

0.38%

Insider Ownership

2.98%

Institutional Own.

20.82%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
MN-166 (ibudilast) Details
Neurological disorder, Degenerative Cervical Myelopathy

Phase 2/3

Data readout

MN-166 (ibudilast) Details
Amyotrophic lateral sclerosis, Neurodegenerative disease

Phase 2/3

Data readout

MN-166 (ibudilast) Details
Neuropathy, Neurological disorder

Phase 2b

Data readout

MN-166 (ibudilast) Details
Alcohol dependence

Phase 2b

Update

MN-001 (tipelukast) Details
Liver disease, Non-alcoholic steatohepatitis

Phase 2

Interim update

MN-166 (ibudilast) Details
Multiple sclerosis, Central nervous system illness

Phase 2

Update

Phase 2

Update

MN-001 (tipelukast) Details
Interstitial lung disease, Lung disease, Idiopathic pulmonary fibrosis

Phase 2

Update

MN-166 (ibudilast) Details
Glioblastoma, Cancer

Phase 2

Update

SAR444836 Details
Phenylketonuria

Phase 1/2

Data readout